Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Contact

News

Penthrox approved in Germany

Apr 4, 2018Cathy WilsonNews

5 April 2018

ASX Announcement

Penthrox approved in Germany

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Germany.

MVP CEO, Mr. John Sharman said, “We are excited that the Marketing Authorisation for Germany has been received.” Germany is one of the most important markets for MVP, as the country is seen by many as a leader in pain drugs and therefore their imprimatur is doubly important for us.

For the full release, please refer to the following link: ASX Announcement – Penthrox Approval in Germany

 

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY23 ASX Announcement

    31 August 2023 ASX Announ...

  • Medical Developments International Ltd awarded up to $1.5M in funding for next generation Penthrox® device

    Media Announcment Medical...

  • FY23 Half Year ASX Announcement

    24 February 2023 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter